Skip to main content
Premium Trial:

Request an Annual Quote

Atossa Genetics, HLB Sign Manufacturing Deal

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Atossa Genetics today announced a manufacturing agreement with HLB for its Mammary Aspirate Specimen Cytology Test for field testing before commercial launch.

Financial terms of the deal were not disclosed.

MASCT is a medical device and method for collecting, shipping, and clinically analyzing nipple aspirate fluid, which contains cells and molecular diagnostic markers that can be used to detect breast cancer as well as cellular changes that may be precursors to breast cancer. The system has been cleared by the US Food and Drug Administration.

The Seattle-based molecular diagnostics company said that it plans to launch MASCT in the Pacific Northwest this year with a wider release in 2012.

Atossa filed for an initial public offering in the fall but withdrew it in February.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.